Serum vs. Scalp DHT: What Finasteride Suppresses and Where

The number on your blood test is not the number that matters most for your hair. Understanding the serum-scalp DHT distinction explains why finasteride works as well as it does and what its ceiling is.

When finasteride is described as reducing DHT, the statement is true but incomplete. DHT is present in different compartments of the body, and finasteride's effect on each compartment is different. The compartment that matters most for androgenetic alopecia is not the one most easily measured on a standard blood test.

Serum DHT: what blood tests measure

Serum DHT is the concentration of dihydrotestosterone in the blood. It reflects the aggregate DHT production from multiple tissues, primarily the liver, prostate, and peripheral skin, all of which express 5-alpha-reductase activity and contribute to circulating DHT levels.

Oral finasteride 1mg daily reduces serum DHT by approximately 65–70% at steady state (reached after approximately two weeks of daily dosing). This is the number that appears on standard blood tests, and it is sometimes ordered to confirm that a patient is taking the medication and absorbing it adequately.

The serum DHT number matters for systemic androgen effects but is not directly the driver of hair follicle miniaturisation in androgenetic alopecia.

Scalp DHT: what matters for hair loss

Androgenetic alopecia is driven by DHT acting locally at the level of the dermal papilla cells within the hair follicle. DHT in this compartment is produced primarily by 5-alpha-reductase type 2 activity within the follicle itself — the enzyme converts testosterone arriving at the follicle to DHT on-site. The DHT then binds to androgen receptors in the dermal papilla, activating gene expression changes that progressively shorten the anagen (growth) phase.

Measuring scalp DHT requires a scalp biopsy or skin sample — it is not accessible on a standard blood test. What research studies using these methods show:

• Scalp DHT suppression with oral finasteride 1mg is approximately 60–70%, slightly lower than serum suppression
• The scalp DHT reduction on finasteride 1mg is clinically sufficient to produce the observed hair density improvements in responders
• Some residual scalp DHT production continues via type 1 5-AR activity that finasteride does not address

Why the two measures diverge

The divergence between serum and scalp DHT suppression reflects the tissue-specific enzyme distribution described in more detail in the 5-AR Type 1 vs. Type 2 article. In short: serum DHT is produced by a combination of type 1 and type 2 activity across multiple tissues. Finasteride suppresses the type 2 contribution; type 1 continues to produce some DHT. Scalp DHT is produced primarily by type 2 within the follicle, but there is also some type 1 contribution from surrounding scalp skin. The net result is slightly lower scalp DHT suppression than serum DHT suppression.

What this means for topical finasteride

The serum/scalp distinction is also the rationale for topical finasteride formulations. Applied directly to the scalp, topical finasteride achieves meaningful local DHT suppression while producing lower systemic absorption and therefore lower serum DHT suppression — a trade-off that is appealing to people concerned about systemic side effects.

Comparative studies show that topical finasteride achieves scalp DHT suppression in a similar range to oral, with serum DHT suppression considerably lower (typically around 20–30% for optimised topical formulations versus 65–70% for oral). The clinical hair density outcomes in comparative studies show similar but not identical results.

Should you get your DHT tested?

A serum DHT test is not required before starting finasteride and is not part of standard finasteride monitoring. Where it is useful:

• Confirming that the medication is being absorbed (a very low serum DHT level confirms the drug is working pharmacologically)
• Baseline before starting, if you want a pharmacological reference point
• When evaluating whether to transition to dutasteride (persistent shedding with high-normal serum DHT on finasteride may indicate incomplete type 2 suppression)

For most people starting a standard finasteride protocol, the clinical assessment of response — shedding rate, photograph comparison, hair pull test — is more practically useful than serum DHT monitoring. The number is informative; it is not the primary measure.